{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:34:35Z","timestamp":1771907675403,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Few patients can reach transmural remission in Crohn\u2019s disease (CD) with currently available therapies. Proactive optimization of infliximab (IFX) based on trough levels may potentially improve these results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective cohort study including consecutive CD patients starting treatment with IFX. Rates of transmural remission were compared between patients with and without therapeutic drug monitoring (target level: 5-7 \u00b5g\/mL). A propensity score\u2013matched analysis was performed to adjust for potential confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 195 CD patients were included, 57.9% receiving proactive therapeutic drug monitoring. The rates of transmural remission were higher in patients under proactive therapeutic drug monitoring (37.2% vs 18.3%; P\u2005=\u2005.004) with similar results in the propensity score\u2013matched analysis (34.2% vs 17.1%; P\u2005=\u2005.025). In multivariate analysis, proactive therapeutic drug monitoring was independently associated with transmural remission (odds ratio, 2.95; 95% confidence interval, 1.44-6.06; P\u2005=\u2005.003).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Proactive optimization of IFX based on trough levels increases the rates of transmural remission in CD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izad272","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T12:21:07Z","timestamp":1700482867000},"page":"1974-1982","source":"Crossref","is-referenced-by-count":7,"title":["Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn\u2019s Disease: A Propensity Score\u2013Matched Analysis"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2947-8791","authenticated-orcid":false,"given":"Samuel Raimundo","family":"Fernandes","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia da Faculdade de Medicina de Lisboa , Lisbon ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]},{"given":"S\u00f3nia","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]},{"given":"Sofia","family":"Saraiva","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]},{"given":"Ana","family":"Rita Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]},{"given":"Paula","family":"Moura Santos","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia da Faculdade de Medicina de Lisboa , Lisbon ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]},{"given":"Ana","family":"Valente","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]}]},{"given":"Lu\u00eds","family":"Ara\u00fajo Correia","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia da Faculdade de Medicina de Lisboa , Lisbon ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-8744","authenticated-orcid":false,"given":"Helena","family":"Cortez-Pinto","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universit\u00e1rio Lisboa Norte EPE , Lisbon ,","place":["Portugal"]},{"name":"Cl\u00ednica Universit\u00e1ria de Gastrenterologia da Faculdade de Medicina de Lisboa , Lisbon ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]},{"name":"Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto ,","place":["Portugal"]}]}],"member":"286","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"4","key":"2024110408182098100_CIT0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","article-title":"Long-term evolution of disease behavior of Crohn\u2019s disease","volume":"8","author":"Cosnes","year":"2002","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2024110408182098100_CIT0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ueg2.12356","article-title":"Transmural remission improves clinical outcomes up to 5 years in Crohn\u2019s disease","volume":"11","author":"Fernandes","year":"2023","journal-title":"United European Gastroenterol J."},{"issue":"8","key":"2024110408182098100_CIT0003","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/apt.15190","article-title":"One-year clinical outcomes with biologics in Crohn\u2019s disease: transmural healing compared with mucosal or no healing","volume":"49","author":"Castiglione","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2024110408182098100_CIT0004","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/apt.16232","article-title":"Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn\u2019s disease","volume":"53","author":"Lafeuille","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"12","key":"2024110408182098100_CIT0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.12998\/wjcc.v6.i12.501","article-title":"Treat-to-target in Crohn\u2019s disease: will transmural healing become a therapeutic endpoint","volume":"6","author":"Serban","year":"2018","journal-title":"World J Clin Cases."},{"issue":"1","key":"2024110408182098100_CIT0006","doi-asserted-by":"crossref","first-page":"e00442","DOI":"10.14309\/ctg.0000000000000442","article-title":"Combined endoscopic and radiologic healing is associated with a better prognosis than endoscopic healing only in patients with Crohn\u2019s disease receiving anti-TNF therapy","volume":"13","author":"Oh","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"issue":"9","key":"2024110408182098100_CIT0007","first-page":"1928","article-title":"Transmural healing evaluated by bowel sonography in patients with Crohn\u2019s disease on maintenance treatment with biologics","volume":"19","author":"Castiglione","year":"2013","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2024110408182098100_CIT0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ibd\/izz131","article-title":"Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease","volume":"26","author":"Fernandes","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"12","key":"2024110408182098100_CIT0009","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/MEG.0000000000002111","article-title":"Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease","volume":"33","author":"Fernandes","year":"2021","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"5","key":"2024110408182098100_CIT0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"3","key":"2024110408182098100_CIT0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology."},{"issue":"11","key":"2024110408182098100_CIT0012","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","article-title":"Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: a systematic review with meta-analysis","volume":"12","author":"Ricciuto","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"4","key":"2024110408182098100_CIT0013","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","article-title":"Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis","volume":"163","author":"Nguyen","year":"2022","journal-title":"Gastroenterology."},{"issue":"7","key":"2024110408182098100_CIT0014","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/MIB.0000000000001126","article-title":"Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease","volume":"23","author":"Kelly","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024110408182098100_CIT0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology."},{"issue":"12","key":"2024110408182098100_CIT0016","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2024110408182098100_CIT0017","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ecco-jcc\/jjw007","article-title":"Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease","volume":"10","author":"Moore","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2024110408182098100_CIT0018","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cgh.2020.04.052","article-title":"Infliximab exposure associates with radiologic evidence of healing in patients with Crohn\u2019s disease","volume":"19","author":"Bossuyt","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"2024110408182098100_CIT0019","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/ecco-jcc\/jjac185","article-title":"Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn\u2019s disease","volume":"17","author":"Takenaka","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"23","key":"2024110408182098100_CIT0020","doi-asserted-by":"crossref","first-page":"1192827","DOI":"10.3389\/fimmu.2023.1192827","article-title":"Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn\u2019s disease","volume":"14","author":"Choi","year":"2023","journal-title":"Front Immunol."},{"issue":"12","key":"2024110408182098100_CIT0021","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)."},{"issue":"4","key":"2024110408182098100_CIT0022","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/j.cgh.2021.03.030","article-title":"Ultrasonography tight control and monitoring in Crohn\u2019s disease during different biological therapies: a multicenter study","volume":"20","author":"Calabrese","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10114","key":"2024110408182098100_CIT0023","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicenter, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet."},{"issue":"3","key":"2024110408182098100_CIT0024","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"17","key":"2024110408182098100_CIT0025","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA."},{"issue":"4","key":"2024110408182098100_CIT0026","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","article-title":"Therapeutic drug monitoring of biologics during induction to prevent primary non-response","volume":"14","author":"Sparrow","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"11","key":"2024110408182098100_CIT0027","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ibd.22902","article-title":"Doubling the infliximab dose versus halving the infusion intervals in Crohn\u2019s disease patients with loss of response","volume":"18","author":"Katz","year":"2012","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad272\/53587136\/izad272.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/11\/1974\/59882157\/izad272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/11\/1974\/59882157\/izad272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:18:39Z","timestamp":1730708319000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/11\/1974\/7429359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,20]]},"published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad272","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2023,11,20]]}}}